Described herein are methods and related compositions for inducing differentiation of human pluripotent stem cells (hPSCs) into hemogenic endothelium with pan-myeloid potential or restricted potential, by forced expression in the hPSCs of a combination of transcription factors as described herein.

Provided is a method for efficiently manufacturing high-purity peripheral nerve cells from undifferentiated cells. The method for manufacturing peripheral nerve cells from undifferentiated cells having an ability to differentiate into peripheral nerve cells includes the following steps (a) and (b): (a) culturing undifferentiated cells having an ability to differentiate into peripheral nerve cells to induce differentiation into neural progenitor cells without detaching a grown colony from a culture vessel; and (b) detaching the neural progenitor cells produced in the step (a) from the culture vessel, then seeding the cells at a seeding density of 2×10.sup.5 to 6×10.sup.5 cells/cm.sup.2 to a culture vessel, and culturing the cells for 14 to 42 days.

The present invention provides a cell treatment apparatus capable of treating cells in a cell culture vessel. The cell treatment apparatus 100 according to the present invention includes a first region 1, a second region 3, and a third region 5. The first region 1 and the second region 3 are placed in succession. The first region 1 is a cell treatment chamber for treating cells. The cell treatment chamber can be closed from the outside of the cell treatment chamber and includes a culture vessel placement portion for placing a cell culture vessel. The second region 3 includes: a laser irradiation device capable of irradiating the cell culture vessel placed in the culture vessel placement portion with a laser; and a spot diameter adjustment device that adjusts a spot diameter formed in a portion to be irradiated with the laser in an object to be irradiated. The third region 5 includes a control device that controls at least one device in the cell treatment apparatus 100 and a power supply device 52 that supplies electric power to at least one device in the cell treatment apparatus 100. The culture vessel placement portion is placed to be adjacent to the second region 3 in the cell treatment chamber. An adjacent portion to the second region 3 in the culture vessel placement portion is translucent.

The present application discloses a method for generating less mature cells from starting cells including inducing the starting cells to revert to a less mature state including increasing the amount of an NME family member whose multimerization state is the biologically active state or decreasing the relative amount of an NME family member whose multimerization state is the biologically inactive state.

There is provided a cell recovery method for recovering cells which are cultured in at least one container containing a liquid medium and adhere to an inner surface of the container, the method including performing: a medium discharge step of discharging the liquid medium from the container; a peeling liquid supply step of supplying a peeling liquid for peeling the cells from the inner surface of the container to the container; a peeling liquid discharge step of discharging the peeling liquid from the container before the cells are completely peeled from the inner surface of the container; a waiting step of waiting until the cells are peeled by action of a residual peeling liquid; and a recovery liquid supply step of supplying a recovery liquid for recovering the cells to the container.

Embodiments of the disclosure concern methods and compositions related to cancer treatment for an individual utilizing recombinant fibroblast cells that comprise one or more activities that are endothelial cell-like. The cells are delivered to a tumor microenvironment following which their death results in destabilization of the tumor vasculature. In particular embodiments, the fibroblast cells recombinantly express one or more of ETV2, FOXC2, and FLI1.

Disclosed herein are cell cultures comprising dorsal and/or ventral PDX1-positive foregut endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified dorsal and/or ventral PDX1-positive foregut endoderm cells as well as methods for enriching, isolating and purifying dorsal and/or ventral PDX1-positive foregut endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of dorsal and/or ventral PDX1-positive foregut endoderm cells, are also disclosed.

The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3′-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.

Embodiments of the present invention provide plant-derived extracts as a replacement for traditional cryoprotectants used to freeze tissue and cells providing a method to decrease post-thaw damage as created by the cryoprotectant. For example, extracts from the genus Hippophae or other plant sources or compositions may be used as a cryoprotectant or may even be used to replace at least some of a traditional cryoprotectant.

This cell treatment device is provided with: a factor introduction device 30 for introducing a pluripotent induction factor into cells so as to prepare induction factor-introduced cells; and a reprogramming suspension culture vessel for culturing the induction factor-introduced cells that have been prepared by the factor introduction device 30.